Publications by authors named "Shumin Fu"

Claim this Profile
D
DDX1 facilitates lenvatinib resistance in hepatocellular carcinoma through regulating ephrin-A3 and activating the Wnt/β-catenin signaling pathway.
Shenglan Huang, Hua Wang, Shumin Fu, Fei Cheng, Kan Liu

Funct Integr Genomics· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety of lenvatinib, sintilimab combined interventional therapy vs bevacizumab, sintilimab combined interventional therapy in intermediate and advanced hepatocellular carcinoma: a multicenter retrospective study.
Yi-Xin Yuan, Lin Xu, Shu-Min Fu, Xiao-Huan Lai, An Li

World J Surg Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and Validation of a Novel Nutritional-Immune-Inflammatory Score Model for Predicting Survival Prognosis in Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Kan Liu, Yaqin Lv, Shumin Fu, Ye Mao, Yongkang Xu

J Inflamm Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.
Shenglan Huang, Kan Liu, Yongkan Xu, Hua Wang, Shumin Fu

Sci Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic pan-cancer analysis identifies PKNOX1 as a potential prognostic and immunological biomarker and its functional validation.
Kan Liu, Yongkang Xu, Ye Mao, Shumin Fu, Shenglan Huang

Front Immunol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
hsa_circ_0008305 facilitates the malignant progression of hepatocellular carcinoma by regulating AKR1C3 expression and sponging miR-379-5p.
Shenglan Huang, Kan Liu, Yongkan Xu, Hua Wang, Shumin Fu

Sci Rep· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of ubiquitination and deubiquitination in cancer lipid metabolism.
Yongkang Xu, Jiayu Zeng, Shumin Fu, Kan Liu, Ye Mao

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma.
Yongkang Xu, Jiayu Zeng, Kan Liu, Dan Li, Shenglan Huang, Shumin Fu

Cell Commun Signal· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Shumin Fu, Yongkang Xu, Ye Mao, Mengting He, Zhimeng Chen

Cancer Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2.
Dan Li, Chen Luo, Jianyong Deng, Yongkang Xu, Shumin Fu

Aging (Albany NY)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.
Yongkang Xu, Shumin Fu, Kan Liu, Ye Mao, Jianbing Wu

Ther Clin Risk Manag· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.
Dan Li, Shenglan Huang, Chen Luo, Yongkang Xu, Shumin Fu

Curr Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma.
Yongkang Xu, Shumin Fu, Ye Mao, Shenglan Huang, Dan Li

Front Med (Lausanne)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Yongkang Xu, Shumin Fu, Kai Shang, Jiayu Zeng, Ye Mao

Front Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma.
Shenglan Huang, Cairong Dong, Jian Zhang, Shumin Fu, Yaqin Lv

Front Mol Biosci· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis